Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Seres’s success with an industrially made bacterial mix in phase 3 trials against Clostridium difficile infection promises an alternative to fecal microbial transplantation in clinical practice.
The first antibody–drug conjugate to treat multiple myeloma can spur reversible loss of vision, but that may not be the case for other anti-BCMA T-cell therapies or bispecific antibodies.
The race to bring vaccines to market is nearing the finish line. Determining which product can best contain the pandemic, however, will take more time.
The imminent large-scale rollout of rapid coronavirus tests promises to aid public health responses to COVID-19 — but a rapid home test remains elusive.
Interest in anti-inflammatory IRAK4 signaling is ramping up, as small-molecule ‘degraders’ that bind both the kinase and E3 ubiquitin ligases prepare to take on traditional kinase inhibitors.
The agency’s ‘no-go’ for BioMarin’s hemophilia A gene therapy came as a surprise, but reflects outstanding questions as to the durability of the treatment.
Several startups are now pursuing the potential of enzymatic synthesis as a faster and more efficient route for synthesizing longer DNA sequences than is possible with traditional chemical means.
Plasma from individuals who have recovered from COVID-19 could benefit sick patients, but definitive evidence for or against convalescent plasma is still lacking. A consensus about how it should be deployed is beginning to emerge—and tools and insights to guide its use are becoming available.
Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.
A deep brain stimulation device capable of fine-tuning output on the basis of patient neuronal activity has been approved for the first time for use in Parkinson’s and a range of other neurological disorders.
Initiatives to gather massive epidemiological datasets aim to cut through national COVID-19 stats in a bid to understand the new coronavirus and aid public health policymakers.
Epizyme’s EZH2 inhibitor gains two approvals in quick succession — a milestone for this new class of epigenetic cancer drug that targets histone marks with greater precision than previous generations.
Emerging clinical trial data suggest that individual immunomodulatory drugs can dampen the hyperactive immune system in severe COVID-19, but polytherapy is the way forward.
Coronavirus is instigating new thinking in diagnostics, such as face masks that can detect viruses on a wearer’s breath or paper-based microfluidics for pathogen identification in low-resource settings.
Concerns persist that COVID-19 vaccines could cause antibody-dependent enhancement, which can potentiate viral entry into host cells and worsen disease.